Clinical comprehensive evaluation of [18F]AlF-FAP-NUR PET: multi-time-point imaging, head-to-head comparison with [18F]FDG.
Purpose: This study was designed to investigate the clinical feasibility of [18F]AlF-FAP-NUR, including the pharmacokinetics, radiation dosimetry estimation, and the head-to-head comparison with [18F]FDG. The head-to-head comparison study was designed to investigate the radiotracer uptake of [18F]Al...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 52; no. 9; pp. 3087 - 3101 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jul2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=186337125&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 186337125 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: Jul2025 vid: 52 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 186337125 183482591 10.1007/s00259-025-07171-9 186337125 ppf: 3087 ppct: 14 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Clinical comprehensive evaluation of [18F]AlF-FAP-NUR PET: multi-time-point imaging, head-to-head comparison with [18F]FDG. aug: au: Zhang, Ziqi Liu, Shaoyu Liang, Sihao Bai, Xuejing He, Yulu Zhong, Jiawei Liang, Wanmei Hou, Peng Zhong, Huizhen Wu, Tingfan Ng, Yee Ling Zhang, Jing Ke, Miao Fu, Yimin Wang, Xinlu affil: https://ror.org/00z0j0d77 Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, 510120, Guangzhou, China sug: ab: Purpose: This study was designed to investigate the clinical feasibility of [18F]AlF-FAP-NUR, including the pharmacokinetics, radiation dosimetry estimation, and the head-to-head comparison with [18F]FDG. The head-to-head comparison study was designed to investigate the radiotracer uptake of [18F]AlF-FAP-NUR, to detect the primary and metastatic lesions in patients with various solid cancers, and to compare the results with those of [18F]FDG PET/CT. The correlation of FAP-expression (H-scores) and standardized uptake values (SUVs) derived from [18F]AlF-FAP-NUR were also included. Methods: Ten patients participated in a multi-time-point imaging protocol aimed at assessing pharmacokinetics and estimating radiation dosimetry. Radiation dosimetry calculations were performed using the OLINDA/EXM 2.0 software. For the comparative analysis between [18F]AlF-FAP-NUR and [18F]FDG PET, a cohort of 35 patients was included. SUVs and tumor-to-background ratios (TBRs) for primary and metastatic lesions were systematically collected and analyzed. To evaluate FAP expression in tissue samples, H-scores were obtained from FAP-immunohistochemistry (FAP-IHC) analyses of samples from 28 patients and correlated with the SUVs measured in [18F]AlF-FAP-NUR PET scans. Statistical analyses included non-parametric tests and correlation assessments, with a significance threshold set at P < 0.05. Results: The study of multi-time-point imaging demonstrated that tumor SUVmax and TBRs increased over time, quickly peaking and remaining in a plateau phase [18F]AlF-FAP-NUR was mainly excreted from kidneys. The effective radiation dose of [18F]AlF-FAP-NUR was approximately 1.90E-02 mSv/MBq. In the head-to-head comparative study, [18F]AlF-FAP-NUR exhibited excellent detection capabilities for both primary and metastatic lesions, particularly in lymph node, bone, and lung metastases. The sensitivity and specificity of [18F]AlF-FAP-NUR PET/CT imaging for detecting lesions, as confirmed by pathology, were 86.7% and 98.3%, respectively. The positive predictive value (PPV) reached 89.7%, more than double that of [18F]FDG (PPV for FDG: 42.3%). Correlation analysis of the SUVs of [18F]AlF-FAP-NUR and FAP expression (based on H-score) showed that SUVs were all strongly correlated with FAP expression, with the SUVmax correlation value being as high as 0.7729 (P < 0.001). Conclusion: Our pilot study in patients with various solid tumors has demonstrated acceptable radiation dosimetry, favorable biodistribution, and significant [18F]AlF-FAP-NUR uptake in FAP-expressing tumors. The strong correlation with FAP expression further indicates the potential clinical usability of [18F]AlF-FAP-NUR PET. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|